ANIK Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: May 11, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Anika Therapeutics Inc (ANIK)

Based on 8 analysts giving stock ratings to Anika Therapeutics Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
38
Buy
49
Hold
13
Sell
0
Strong Sell
0
Anika Therapeutics Inc

Anika Therapeutics Inc. Stock Analysis ANIK

United States Health Care Micro Cap Report:
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Read More

Anika Therapeutics Inc (ANIK) Chart

Key Statistics of Anika Therapeutics Inc (ANIK)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$14.57$15.39

Today's Open

$15.16

Volume

71.16K

P/E Ratio (TTM)

-

52 Week Range

$7.87$16.24

Market Cap

198.92M

Avg. Volume

116.36K

Dividend Yield

-

Financial Metrics & Statements of Anika Therapeutics Inc (ANIK)

FAQ's for Anika Therapeutics Inc (ANIK)

  • According to Musaffa’s Shariah screening methodology, Anika Therapeutics Inc (ANIK) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.